drugset / Trial / NCT00566111

Ceftriaxone in the Management of Bipolar Depression

NCT00566111

RandomizedParallel-groupQuadruple-blindTreatment

Summary

We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.

Timeline

Start
2007-09
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ceftriaxone Other / unclassified 2 g Intravenous

Indications